Biomedical Research-tokyo最新文献_第9页

Non-invasive Dry Eye detection using Fuzzy c-means Clustering Algorithm 基于模糊c均值聚类算法的无创干眼检测

IF 1.2 4区医学

Biomedical Research-tokyo Pub Date : 2021-01-01 DOI: 10.35841/0970-938X.S1-S5

I.Ch, ra, N.Prabhakaran, V.Prabhu, S.Harshavardhan, N.Duraichi

引用次数: 0

Difficulties and Points of view in Nourishing Directing. 滋补指导的难点与观点。

IF 1.2 4区医学

Biomedical Research-tokyo Pub Date : 2021-01-01 DOI: 10.35841/0970-938X.32.3.S21-S22

S. Ahmed

引用次数: 0

Targeting of the receptor for advanced glycation end products regulates neutrophil infiltration and extravascular recruitment in mice acute pancreatitis. 靶向晚期糖基化终产物受体调节小鼠急性胰腺炎中性粒细胞浸润和血管外募集。

IF 1.2 4区医学

Biomedical Research-tokyo Pub Date : 2021-01-01 DOI: 10.35841/0970-938X.S28-S33

M. Merza, T. Faraj, Rawaz Dilzar Tawfiq, Rundk Hwaiz, Harm, Ali Hama, Younis Sadiq Smael

{"title":"Targeting of the receptor for advanced glycation end products regulates neutrophil infiltration and extravascular recruitment in mice acute pancreatitis.","authors":"M. Merza, T. Faraj, Rawaz Dilzar Tawfiq, Rundk Hwaiz, Harm, Ali Hama, Younis Sadiq Smael","doi":"10.35841/0970-938X.S28-S33","DOIUrl":"https://doi.org/10.35841/0970-938X.S28-S33","url":null,"abstract":"Infiltration of leukocytes and pancreatic acinar cell damaging are good indicators of extreme Acute Pancreatitis (AP). The signaling pathways for inflammation and tissue damage of the pancreas not been elucidated yet. In this study, we evaluated the role of targeting of the Receptor for Advanced Glycation End products (RAGE) signaling in AP. Moreover, we investigated the role of signaling RAGE in AP. C57BL/6 mice were injected with a RAGE inhibitor (anti-RAGE) (500 μg/kg) before induction of taurocholate into the pancreatic duct to induce pancreatitis. Treatment anti-RAGE decreased blood amylase concentration, neutrophil recruitment in the pancreas, hemorrhage and edema formation in pancreatitis decreased by taurocholate. Additionally, anti-RAGE administration decreased the MPO activity in the pancreas and lung induced by taurocholate. Intraperitoneal (IP) injection of anti-RAGE significantly decreased concentrations of CXCL2 and IL-6 in the pancreas and plasma respectively in response to challenges of taurocholate. Finally, RAGE inhibition did not have a direct impact on secretagogue-induced trypsinogen activation in pancreatic acinar cells in vitro. Thus, these findings show new signaling pathways in AP and suggest that RAGE targeting may be an efficient way to improve extreme AP.","PeriodicalId":9138,"journal":{"name":"Biomedical Research-tokyo","volume":"3 1","pages":"28-33"},"PeriodicalIF":1.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82053239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Estimation level of IL-10 and TNF-? in Iraq T1DM patient. IL-10和TNF-?伊拉克的T1DM患者。

IF 1.2 4区医学

Biomedical Research-tokyo Pub Date : 2021-01-01 DOI: 10.35841/0970-938X.32.3.75-75

Sabreen Ali Mezil, R. Al-Shawk

引用次数: 0

Effect of UGT2B7 Gene Polymorphism with Clinical Pediatric Epileptic patients on Sodium Valproate Monotherapy 临床儿童癫痫患者UGT2B7基因多态性对丙戊酸钠单药治疗的影响

IF 1.2 4区医学

Biomedical Research-tokyo Pub Date : 2021-01-01 DOI: 10.35841/0970-938X.S10-S15

ith Pb, Sachidan, A. Adiga, U. Adiga, V. Shenoy, S. Kumari, P. Shetty, S. Shetty, K. Sharmila

{"title":"Effect of UGT2B7 Gene Polymorphism with Clinical Pediatric Epileptic patients on Sodium Valproate Monotherapy","authors":"ith Pb, Sachidan, A. Adiga, U. Adiga, V. Shenoy, S. Kumari, P. Shetty, S. Shetty, K. Sharmila","doi":"10.35841/0970-938X.S10-S15","DOIUrl":"https://doi.org/10.35841/0970-938X.S10-S15","url":null,"abstract":"Background: Pediatric epilepsy comprises of a chronic neurological disorders characterized by recurrent seizure attack. Sodium valproate is one of the common anti-epileptic drugs used in the treatment. Glucuronide conjugation is the major metabolic pathway of sodium valproate, carried out by the enzyme Uridine 5’-diphospho (UDP) glucuronosyl transferase (UGT) whose genetic polymorphisms may alter clinical outcome. Aim: To find the association between UGT2B7 genetic polymorphism and clinical outcome in terms of efficacy and tolerability in pediatric epileptic patients on sodium valproate monotherapy. Methods and Materials: In this cohort study, 75 pediatric epileptic patients aged 2-18 years receiving sodium valproate monotherapy for past one month were included from Justice K S Hegde Charitable Hospital, Mangalore, India after obtaining informed consent. Genetic polymorphism patterns of UGT2B7 (C161T, A268G, G211T) was evaluated by PCR-RFLP. Clinical outcome was measured in terms of responders and non-responders based on seizure control during the 6 month observation period. Tolerability was measured by estimating the hepatic, renal and other lab parameters. Clinical outcome in different UGT genotypes was compared by Chi square test. P value <0.05 was considered as significant. Results: Out of 75 patients, CC (41.3%), CT (38.7%), TT (20%) pattern was observed in UGT2B7 (C161T) gene, AA(14.7%), AG(42.7%), GG(42.7%) in (A268G) gene and GG(80%), GT(18.7%), TT(1.3%) in (G211T) gene. It was found that there was no statistical difference in clinical outcome with different UGT2B7 genetic polymorphism patterns. Conclusion: We conclude from our study that genetic polymorphism of UGT2B7 doesn’t have any role on the clinical outcome of epilepsy.","PeriodicalId":9138,"journal":{"name":"Biomedical Research-tokyo","volume":"17 1","pages":"10-15"},"PeriodicalIF":1.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75241050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cellular expression and subcellular localization of diacylglycerol kinase γ in rat brain. 二酰基甘油激酶γ在大鼠脑中的细胞表达和亚细胞定位。

IF 1.2 4区医学

Biomedical Research-tokyo Pub Date : 2021-01-01 DOI: 10.2220/biomedres.42.33

Yasukazu Hozumi, Tomoyuki Nakano, Kaoru Goto

{"title":"Cellular expression and subcellular localization of diacylglycerol kinase γ in rat brain.","authors":"Yasukazu Hozumi, Tomoyuki Nakano, Kaoru Goto","doi":"10.2220/biomedres.42.33","DOIUrl":"https://doi.org/10.2220/biomedres.42.33","url":null,"abstract":"Gq protein-coupled receptors lead to activation of phospholipase C, which triggers phosphoinositide signaling. Diacylglycerol (DG) is one of the phosphoinositide metabolites and serves as a second messenger. Diacylglycerol kinase (DGK) phosphorylates DG to produce another second messenger phosphatidic acid. Of the DGK family, DGKγ is predominantly expressed in the brain at the mRNA level. Recent studies have shown the expression of DGKγ in vascular endothelial cells and adrenal medullary cells at the protein level, although its detailed cellular expression pattern and subcellular localization in the brain remain to be determined. In the present study, we addressed this point using specific DGKγ antibody. DGKγ was expressed in both projection neurons and interneurons in the cerebral cortex, hippocampal formation, and cerebellum. In cerebellar Purkinje cells, DGKγ was distributed to the soma and dendrites. Fractionation study revealed that DGKγ was enriched in the internal membranes containing the endoplasmic reticulum and Golgi complex. In immunoelectron microscopy, DGKγ was localized throughout the smooth endoplasmic reticulum system. These findings suggest that DGKγ shows unique cellular expression pattern in the brain and distinct subcellular localization different from other DGK isozymes.","PeriodicalId":9138,"journal":{"name":"Biomedical Research-tokyo","volume":"42 1","pages":"33-42"},"PeriodicalIF":1.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25353635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New conjugated monoclonal antibodies: Area of a promising therapy in metastatic breast cancer. 新的偶联单克隆抗体:转移性乳腺癌的一个有希望的治疗领域。

IF 1.2 4区医学

Biomedical Research-tokyo Pub Date : 2021-01-01 DOI: 10.35841/0970-938X.32.1.15-18

EL Hazzaz Reda, Oualla Karima, Darif Khadija, Sqalli Houssaini Med, Amaadour Lamiae, B. Zineb, A. Samia, M. Nawfel

{"title":"New conjugated monoclonal antibodies: Area of a promising therapy in metastatic breast cancer.","authors":"EL Hazzaz Reda, Oualla Karima, Darif Khadija, Sqalli Houssaini Med, Amaadour Lamiae, B. Zineb, A. Samia, M. Nawfel","doi":"10.35841/0970-938X.32.1.15-18","DOIUrl":"https://doi.org/10.35841/0970-938X.32.1.15-18","url":null,"abstract":"Following advances in molecular biology and better understanding of the mechanisms of carcinogenesis, new therapies have been developed with new agents that target tumor cells with minimal effects on normal cells. Monoclonal antibodies represent the model of success of this approach; they are directed against antigens selectively expressed by tumor cells. The conjugation of these monoclonal antibodies with potent cytotoxic drugs makes it possible to improve their efficacy while maintaining a favorable tolerance profile. T-DM1 (Trastuzumab Emtansine) is the first example of advanced development of a conjugated antibody. It works by associating an antitumor activity specific to trastuzumab with the efficient delivery of a potent cytotoxic, delivered selectively and targeted to cancer cells overexpressing HER2. Unlike trastuzumab emtansine, trastuzumab deruxtecan has a released payload that easily crosses the cell membrane, which potentially allows for a potent cytotoxic effect on neighboring tumor cells regardless of target expression. In addition, the released payload has a short half-life, which is designed to minimize systemic exposure. DESTINY breast-01 study has demonstrated the efficacy of trastuzumab deruxtecan in patients with HER2- positive metastatic breast cancer previously treated with trastuzumab emtansine. Trastuzumab deruxtecan is FDA-approved. Sacituzumab govitecan (sacituzumab govitecan-hziy) is a conjugated monoclonal antibody developed by site-specific conjugation of the active metabolite of irinotecan, SN-38 (govitecan). It has demonstrated promising activity in advanced lines for triple-negative breast cancer in a phase I/II study and recently in ASCENT trial phase III. Conjugated monoclonal antibodies have been shown to be effective in different subtypes of metastatic breast cancer.","PeriodicalId":9138,"journal":{"name":"Biomedical Research-tokyo","volume":"67 1","pages":"15-18"},"PeriodicalIF":1.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84047698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of application of navigation system to odontogenic benign tumors with maxilla. 导航系统在上颌骨牙源性良性肿瘤中的应用。

IF 1.2 4区医学

Biomedical Research-tokyo Pub Date : 2021-01-01 DOI: 10.35841/0970-938X.32.2.37-41

Julia Koseki, Takahiro Abe, Y. Miyamoto, M. Kashiwagi, Makiko Ishibashi, Asako Taniguchi, H. Suenaga, H. Abe, Masanobu Abe, K. Hoshi

引用次数: 0

Cellular expression of CD26/dipeptidyl peptidase IV. CD26/二肽基肽酶IV的细胞表达。

IF 1.2 4区医学

Biomedical Research-tokyo Pub Date : 2021-01-01 DOI: 10.2220/biomedres.42.229

Toshihiko Iwanaga, Junko Nio-Kobayashi

{"title":"Cellular expression of CD26/dipeptidyl peptidase IV.","authors":"Toshihiko Iwanaga, Junko Nio-Kobayashi","doi":"10.2220/biomedres.42.229","DOIUrl":"https://doi.org/10.2220/biomedres.42.229","url":null,"abstract":"Dipeptidyl peptidase 4 (DPP4), a serine protease expressed on luminal and apical cell membrane, is identical to the lymphocyte cell surface protein CD26. DPP4 rapidly deactivates hormones and cytokines by cleaving their NH2-terminal dipeptides. Its functions are based on membrane digestion and/or binding of bioactive peptides, signal molecules, and extracellular matrix components. The soluble form is also present in body fluids such as serum, urine, semen, and synovial fluid. The extremely broad distribution of CD26/DPP4 indicates its divergent roles depending on cell type and activated conditions. The cellular localization was earlier examined by enzyme histochemistry and subsequently by immunohistochemistry. Although immunohistochemical analyses are higher in specificity and easier to use at electron microscopic levels than enzyme histochemistry, the immunoreaction is considerably affected by the animal species, types of tissue sections, and specificity of antibodies. Understanding of the functional significance and advancement of its clinical use (diagnosis and treatment of diseases) require precise information on the cellular distribution including subcellular localization and pathological changes. This short review summarizes in particular immunohistochemical findings on CD26/DPP4.","PeriodicalId":9138,"journal":{"name":"Biomedical Research-tokyo","volume":"42 6","pages":"229-237"},"PeriodicalIF":1.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39749586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Genomic profiling of multiple tissues in two patients with multiple endocrine neoplasia type 1. 2例1型多发性内分泌瘤多组织的基因组分析。

IF 1.2 4区医学

Biomedical Research-tokyo Pub Date : 2021-01-01 DOI: 10.2220/biomedres.42.89

Akane Naruoka, Sumiko Ohnami, Takeshi Nagashima, Masakuni Serizawa, Keiichi Hatakeyama, Keiichi Ohshima, Shumpei Ohnami, Kenichi Urakami, Yasue Horiuchi, Yoshimi Kiyozumi, Hiroyuki Matsubayashi, Masato Abe, Takuma Ohishi, Toru Kameya, Takashi Sugino, Tetsuro Onitsuka, Mitsuhiro Isaka, Yasuhisa Ohde, Teiichi Sugiura, Takaaki Ito, Katsuhiko Uesaka, Yasuto Akiyama, Masatoshi Kusuhara, Ken Yamaguchi

{"title":"Genomic profiling of multiple tissues in two patients with multiple endocrine neoplasia type 1.","authors":"Akane Naruoka, Sumiko Ohnami, Takeshi Nagashima, Masakuni Serizawa, Keiichi Hatakeyama, Keiichi Ohshima, Shumpei Ohnami, Kenichi Urakami, Yasue Horiuchi, Yoshimi Kiyozumi, Hiroyuki Matsubayashi, Masato Abe, Takuma Ohishi, Toru Kameya, Takashi Sugino, Tetsuro Onitsuka, Mitsuhiro Isaka, Yasuhisa Ohde, Teiichi Sugiura, Takaaki Ito, Katsuhiko Uesaka, Yasuto Akiyama, Masatoshi Kusuhara, Ken Yamaguchi","doi":"10.2220/biomedres.42.89","DOIUrl":"https://doi.org/10.2220/biomedres.42.89","url":null,"abstract":"Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant tumor syndrome. This hereditary cancer is caused by germline variants in MEN1. Two patients with MEN1 were identified via whole exome sequencing and gene expression profile analysis, conducted for 5,063 patients with various types of cancers. We obtained multiple tumors from each patient; tumors derived from these two MEN1 patients had a loss of the normal MEN1 allele and frequently chromosomal copy number changes. Thus, we investigated whether structural variants were present in the MEN1 patient genomes. Whole-genome sequencing revealed no catastrophic rearrangements, and the tumor samples had very low somatic variants. The two patients had germline variants in MEN1 and some chromosomal copy number changes including on chromosome 11. The only pathogenic variant detected was the MEN1 germline variant, and chromosomal rearrangements led to tumorigenesis in somatic cells. Furthermore, the MEN1 tumor samples displayed a specific signature characterized by T:A>C:G transition. Studies of multiple tumors obtained from single patients are rare in hereditary cancer syndromes, and our results provide insights that the second hit of the tumor suppressor gene MEN1 may be caused by a gross genome rearrangement, not a small insertion and deletion, nor a change in epigenetic regulation.","PeriodicalId":9138,"journal":{"name":"Biomedical Research-tokyo","volume":"42 2","pages":"89-94"},"PeriodicalIF":1.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25589574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0